NCCR Urges Congress to Support Senate Bill for Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--The National Coalition for Cancer Research (NCCR) has activated its 18 member organizations to write to Congress in support of S.1897, the NIH Revitalization Act of 1996. This legislation was introduced in the US Senate by Sen. Nancy Kassebaum (R-KS) to revise and extend certain programs of the NIH, including the National Cancer Institute (NCI).

WASHINGTON--The National Coalition for Cancer Research (NCCR)has activated its 18 member organizations to write to Congressin support of S.1897, the NIH Revitalization Act of 1996. Thislegislation was introduced in the US Senate by Sen. Nancy Kassebaum(R-KS) to revise and extend certain programs of the NIH, includingthe National Cancer Institute (NCI).

The legislation authorizes funding for the NCI at $3 billion andstrikes various cancer-specific earmarks, ie, allocations forbreast cancer, ovarian cancer, and prostate cancer. The NCCR supportsa balanced cancer research agenda and believes that earmarkingof site- and gender-specific research should not be supportedunless additional funds are provided for these priorities.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.